+0.04  (+3%)
Previous Close 1.28
Open 1.33
Price To Book 2.28
Market Cap 63322608
Shares 47,971,673
Volume 485,294
Short Ratio
Av. Daily Volume 1,423,138

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 dosing of first patient announced October 15, 2018.
SCY-078 - oral - CARES
Candida Auris
Phase 2 trial initiated 3Q 2018.
Ibrexafungerp (SCY-078)
Invasive aspergillosis
Phase 3 data due 1H 2020.
SCY-078 - oral ibrexafungerp - VANISH
Vulvovaginal candidiasis (VVC)
Phase 3 open label interim data released January 30, 2019 - 11/17 partial or complete responses.
SCY-078 - oral (FURI)
Invasive candidiasis

Latest News

  1. 4 Biotech Stocks Making Moves On Thursday (1/31/19)
  2. SCYNEXIS Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies
  3. SCYNEXIS Announces Appointment of Industry Veteran Armando Anido to its Board of Directors
  4. Does SCYNEXIS, Inc.’s (NASDAQ:SCYX) CEO Salary Reflect Performance?
  5. Antimicrobials Working Group Announces Updates to Leadership Team
  6. The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO
  7. SCYNEXIS Provides Year-end Update and Outlines Plans for 2019
  8. SCYNEXIS, Inc. to Present at Upcoming Investor Conferences
  9. Scynexis (SCYX) Reports Q3 Loss, Tops Revenue Estimates
  10. Scynexis: 3Q Earnings Snapshot
  11. SCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company Update
  12. SCYNEXIS Announces FDA Agreement with Company-Proposed Phase 3 Vulvovaginal Candidiasis Program for Oral Ibrexafungerp
  13. SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)
  14. SCYNEXIS Supports AMR Challenge and Fungal Disease Awareness Week
  15. SCYNEXIS to Present an Overview of the Company's Pipeline at IDWeek 2018
  16. Who Owns SCYNEXIS Inc (NASDAQ:SCYX)?
  17. 5 Healthcare Stocks That Are Down, But Not Out!
  18. SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences